The Peptide Desk The Peptide Desk

This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon
Lexicon

Pantoprazole (Protonix)

Proton pump inhibitor with 24-hour action - timing decides half the effect.

3 min read 6 sources

To the sources
Blue 3D molecule with a yellow sulphur atom above a white podium in a bright lab
Compound approved · since 2000

Summary

At a glance

Sources checked on 26 Oct 2026

Oesophagitis resolved after 8 weeks
88 %

Erosive oesophagitis, highest level, placebo 33 percent4

Important stomach bleeding on ventilation
1.0 %

Placebo 3.5 percent, 4,821 ICU patients, given into the vein2

Largest safety trial
~3 years

17,598 participants against placebo, median 3.01 years3

Enteric infections
1.4 %

Only difference in the safety trial, placebo 1.0 percent3

  • Pantoprazole blocks the proton pump in the parietal cells of the stomach and with it the last step of acid production.6
  • In erosive oesophagitis inflammation resolved after 8 weeks in 59 to 88 percent depending on the level, on placebo in 33 percent.4
  • In intensive care it lowered clinically important stomach bleeding but did not change mortality at 90 days. There it was given into the vein.12
  • In the largest safety trial over about three years only enteric infections were slightly more common than on placebo.3
  • Everything here is the state of research, not a recommendation.6
Profile

Updated July 2026

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~1 hour

Half-life ~1 hour
After 2 hours: 25 %
Hour 1 · 50 %Hour 2 · 25 %Hour 3 · 12.5 %Hour 5 · 3.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Class
Proton pump inhibitor

PPI

Use
Oral

once daily, 30 to 60 minutes before food

Half-life
about 1 hour

effect still lasts 24 hours

Why
The binding to the pump is irreversible
Long-term use
Check magnesium

B12, calcium and iron

Contents 12 sections
  1. At a glance
  2. What is pantoprazole?
  3. How it works
  4. Use and dosing
  5. What the research shows
  6. Research status
  7. Side effects
  8. Storage
  9. Related compounds
  10. FAQ
  11. Glossary
  12. Sources

What is pantoprazole?

Pantoprazole is a proton pump inhibitor. It blocks the H+/K+-ATPase in the parietal cells of the stomach, meaning the proton pump and with it the final step of acid production. Because the binding is irreversible, the effect lasts around 24 hours even though half the drug itself is cleared after about an hour.

That discrepancy is the core of the substance: you are not dosing a blood level, you are switching pumps off permanently. The body has to build new ones. That takes time.

In the context of this platform, pantoprazole matters because oral compounds and anti-inflammatories put load on the stomach.

This information is for research and educational purposes only. No medical advice.

Comparison

Supporting drugs in the lexicon

Drugs for stomach, bile and liver, as stated in the TPD lexicon. Tap a card to open its entry.

Proton pump inhibitor Pantoprazole (Protonix) H+/K+-ATPase
Bile acid Ursodeoxycholic acid (Ursodiol) Milk thistle plant extract Silymarin (milk thistle)

Simplified: only pantoprazole lowers stomach acid, the others act on bile and liver. 6

How it works

The decisive point is timing. That is exactly where it usually goes wrong in practice. Proton pump inhibitors only block active pumps. Pumps become active through food. Taking the tablet fasted and then waiting half an hour to an hour lines the drug peak up with the freshly activated pumps. Taking it after the meal forfeits a large part of the effect, because the peak has passed by the time the pumps start up.

For the same reason the full effect is not there on day one. It takes two to three days until enough pumps are permanently blocked.

Where it acts

Where pantoprazole acts and what trials saw

Tap a point or a card. Colour = proton pump, grey = observed in studies.

  1. Stomach

    Blocks the proton pump in parietal cells, less acid, fewer important bleeds in intensive care6

    H+/K+-ATPase
  2. Gut

    Enteric infections slightly more common, 1.4 instead of 1.0 percent over three years3

    Observed in trials
  3. Lung

    Pneumonia not more common than on placebo3

    Observed in trials
  4. Bone

    Fractures not more common than on placebo3

    Observed in trials
  5. Kidney

    Chronic kidney disease not more common than on placebo3

    Observed in trials

Targets in the ChEMBL database6

Compound CHEMBL1502: one recorded mechanism, Inhibitor.

Proton pump (potassium-proton ATPase)
Gene
ATP4A, ATP4B
UniProt
P20648, P51164
ChEMBL
CHEMBL2095173
Action
Inhibitor
Blue molecules with a yellow atom settling onto round glass pumps in a bright cell layer
Pantoprazole shuts down active proton pumps in the stomach lining. Symbolic image.

Use and dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts
White folding box with the TPD logo next to a blister with ten white tablets, two loose tablets in front
Pantoprazole as a tablet in a blister. Symbolic image.

What the research shows

Efficacy in reflux disease is old and uncontested: in the investigation in the American Journal of Gastroenterology (2000), 88 percent of esophagitis cases had healed after eight weeks on 40mg, versus 33 percent on placebo.

The modern intensive care literature is more interesting, because it shows where the limits are. SUP-ICU (NEJM 2018) found no survival advantage in almost 3,300 ICU patients, but fewer clinically relevant bleeds. REVISE (NEJM 2024) confirmed this in ventilated patients and cut relevant bleeding from 3.5 to 1.0 percent, again with no effect on mortality.

For long-term safety the COMPASS substudy (Gastroenterology 2019) is the best available evidence: 17,598 participants over a median of three years, randomised. Apart from a slight increase in enteric infections, no significant harm was found. That defuses a good part of the concern circulating about this class, even if it cannot rule out small effects across decades.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Resolved oesophagitis4

603 participants, three levels against placebo, share in percent

After 4 weeks4
Placebo 14%
Lowest level 42%
Middle level 55%
Highest level (highest study dose, 40 mg per day) 72%
After 8 weeks4
Placebo 33%
Lowest level 59%
Middle level 78%
Highest level (highest study dose, 40 mg per day) 88%

Taken once in the morning. Every level was clearly above placebo, the highest worked strongest and fastest. Symptoms improved at the highest level from the first day.

Clinically important stomach bleeding12

Two large trials, given into the vein, share in percent

SUP-ICU1 3,298 ICU patients at risk of bleeding
Placebo 4.2%
Pantoprazole into the vein 2.5%
REVISE2 4,821 ventilated ICU patients
Placebo 3.5%
Pantoprazole into the vein 1.0%

Both trials saw fewer bleeds. Pneumonia, enteric infections and serious adverse reactions were not more common than on placebo.

Mortality at 90 days12

Share in percent, given into the vein

SUP-ICU1
Placebo 30.4%
Pantoprazole into the vein 31.1%
REVISE2
Placebo 30.9%
Pantoprazole into the vein 29.1%

No clear difference in either trial. Fewer bleeds did not mean longer survival here.

Glass stomach on a stainless steel trolley in a bright clinic room
Trials on reflux, intensive care and long-term safety. Symbolic image.

Research status

Where the research stands

Selection from 258 entries on ClinicalTrials.gov. Many test other drugs and use pantoprazole only alongside. The list shows trials on pantoprazole itself and the large safety trials. As of 26 Oct 2026. 5

  1. Preclinical Blocks the potassium-proton pump in the stomach
  2. Phase 1 2 trials, 2 completed
  3. Phase 2 no registered trial
  4. Phase 3 8 trials, 7 completed
  5. Approval since 2000
5,385 participants in phase 3 Planned figures for running trials Approved: ChEMBL lists pantoprazole with phase 4 and first approval in 2000. The oesophagitis trial dates from the same time and is not in the registry.6
Show all 11 phase 3 and 4 trials on a timelineHide timeline 10 completed 1 running 3 with results
Phase 3
Phase 4

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026. Phase 1: 2 trials on safety and pharmacokinetics, not shown as bars.

Side effects

  • Poorer nutrient uptake: magnesium, vitamin B12, calcium and iron with use over months. The most practically relevant point.
  • Enteric infections: slightly elevated risk, the only finding from the large safety trial.
  • Rebound on stopping: temporarily more acid than before. Hence taper.
  • Headache and diarrhoea: the most common short-term reports, usually mild.

Tolerability

Enteric infections over three years

Out of 100 participants, in how many an enteric infection occurred.

1 of 100 Placebo
1 of 100 Pantoprazole as a tablet
Event PlaceboPantoprazole as a tablet
Enteric infection3 1%1%

Pneumonia, fractures, kidney disease, dementia, cancer and mortality did not differ from placebo. Clostridium difficile infections were about twice as common, but with only 13 cases not certain.34

Storage

Store dry, at room temperature and protected from light. Keep out of reach of children.

Three white tablet bottles and a folded light blue towel on a white shelf
Store dry, at room temperature and protected from light. Symbolic image.

Related

Related compounds

A different path: all in the TPD lexicon.

Pantoprazole (Protonix)
Ursodeoxycholic acid (Ursodiol) Bile acid, acts on bile and liver Silymarin (milk thistle) Plant extract, used in the liver context Prednisone Anti-inflammatory that can strain the stomach Anavar (Oxandrolone) Oral anabolic, named in the entry as a reason for stomach protection

FAQ

Common questions about Pantoprazole (Protonix)

Short answers, each backed by the sources below.

How does pantoprazole work?

Pantoprazole blocks the potassium-proton pump in the parietal cells of the stomach lining. This pump is the last step of acid production. Fewer active pumps mean less stomach acid.6

What did the oesophagitis trial show?

603 participants with erosive oesophagitis received placebo or one of three levels. After 8 weeks the inflammation had resolved in 59, 78 and 88 percent, on placebo in 33 percent. The highest level worked fastest, symptoms improved from the first day. No serious drug-related side effects occurred.4

What did the intensive care trials show?

Two large trials gave pantoprazole into the vein. Clinically important stomach bleeding fell from 4.2 to 2.5 percent (3,298 patients) and from 3.5 to 1.0 percent (4,821 ventilated patients). Mortality at 90 days did not change in either.12

Is long-term use safe?

The best answer comes from a sub-study with 17,598 participants who took pantoprazole or placebo for a median of three years. Only enteric infections were slightly more common (1.4 instead of 1.0 percent). Pneumonia, fractures, kidney disease, dementia and mortality did not differ. This does not rule out very small effects over decades.3

Do the intensive care trials apply to tablets?

Only partly. SUP-ICU and REVISE gave the drug into the vein in seriously ill people. The oesophagitis trial and the safety trial used tablets.1243

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Erosive oesophagitis
Inflammation of the oesophagus with small lining injuries from acid.
Irreversible
Not reversible: the blocked pump stays off and the body has to make new ones.
Parietal cells
Cells of the stomach lining that produce hydrochloric acid.
Placebo
Dummy preparation without active substance. Comparing against it shows what is due to the substance itself.
Proton pump
Enzyme in the parietal cells that pumps acid into the stomach in exchange for potassium.
Proton pump inhibitor (PPI)
Drug class that blocks the acid pump in the stomach.
Rebound
Temporarily more acid than before once the suppression stops.
Reflux
Stomach contents flow back into the oesophagus, often with heartburn.
Stress ulcer prophylaxis
Protection of the stomach in seriously ill people in intensive care who are prone to bleeding.

Evidence

Sources

Show all 6 sourcesHide sources 4 Studies1 Trial registry1 Database checked 26 Oct 2026

Studies

  1. SUP-ICU: pantoprazole for bleeding risk in intensive care

    Krag et al., New England Journal of Medicine, 2018

    DOI 10.1056/NEJMoa1714919 PMID 30354950 NCT02467621
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. REVISE: bleeding prevention during mechanical ventilation

    Cook et al., New England Journal of Medicine, 2024

    DOI 10.1056/NEJMoa2404245 PMID 38875111 NCT03374800
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Safety over three years: COMPASS sub-study

    Moayyedi et al., Gastroenterology, 2019

    DOI 10.1053/j.gastro.2019.05.056 PMID 31152740 NCT01776424
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Three levels against placebo in erosive oesophagitis

    Richter et al., American Journal of Gastroenterology, 2000

    DOI 10.1111/j.1572-0241.2000.03254.x PMID 11095320
    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Pantoprazole trials on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Pantoprazole in ChEMBL (target and approval)

    ChEMBL, EMBL-EBI (CHEMBL1502)

    Checked 26 Oct 2026 via ChEMBL